Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion

Shroff, Daraius; Bhargava, Arun; Sharma, Bhavana; Gupta, Charu; Shroff, Cyrus

doi:10.1007/s00417-010-1353-6

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was shown to be effective in treating macular edema due to RVO. One of the disadvantages of TA treatment is the short-acting feature of the drug and frequent injections and the most important one may be the high percentage of uncontrolled intraocular pressure elevation in these patients (30)(31)(32).…”

Section: Discussionmentioning

confidence: 99%

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Yumuşak

Örnek

Dikel

2016

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Yumuşak

Örnek

Dikel

2016

European Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Twelve-month experience with Ozurdex WJ Mayer et al However, a higher rate of side effects was reported using intravitreal triamcinolone acetonide. [25][26][27][28] Dexamethasone is a potent, water-soluble corticosteroid that can be delivered into the vitreous cavity either by injection of a dexamethasone solution with a very short half-life 29 or by the implantation of an approved dexamethasone intravitreal implant using a customized applicator system (Ozurdex) 6 releasing dexamethasone over a prolonged period until complete resolution of the matrix as shown in the GENEVA trial. 6 Using this approach, a beneficial effect on VA and retinal thickness in patients with macular edema associated with BRVO and CRVO 6 has been reported.…”

Section: Discussionmentioning

confidence: 99%

Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion

Mayer

Wolf

Kernt

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To evaluate the efficacy and safety of a dexamethasone implant (Ozurdex) alone or in combination with bevacizumab. Methods Sixty-four eyes were prospectively investigated. Group 1 (22 central retinal vein occlusion (CRVO) and 16 branch retinal vein occlusion (BRVO)) was treated with Ozurdex alone, and group 2 (14 CRVO and 12 BRVO) was treated with three consecutive bevacizumab injections followed by Ozurdex. Recurrences were treated with Ozurdex only. Patients were seen preoperatively and thereafter in monthly intervals. The primary end point was best-corrected visual acuity (BCVA) at 12 months. Results In group 1, BCVA improved by 6.6 (±1.7) letters in CRVO and 7.8 (±2.9) in BRVO patients, and in group 2 by 9.8 (±1.0) vs 9.4 ( ± 2.1) letters. A significant difference was only seen between CRVO patients in group 1 and 2 at 12 months (Po0.05). Recurrence after the first Ozurdex injection occurred after 3.8 (CRVO) and 3.5 months (BRVO) in group 1, vs 3.2 and 3.7 months in group 2. Elevated intraocular pressure (45 mm Hg) was measured in approximately 40% cataract progression requiring surgery in about 50% of eyes after three Ozurdex injections. Conclusion Combined treatment showed slightly better functional outcome for CRVO patients. Increased intraocular pressure and cataract progression was frequent and should be considered when an individual treatment is planned.

show abstract

“…To reduce the number of injections, it would be effective (1) to distinguish those patients who do not require retreatment,20,21 (2) to design the optimum dosing and sequence,14,17,22,23 or (3) to switch to some other treatment if anti-VEGF therapy is not effective. In the current study, we aimed to reduce the number of IVB in eyes with recurrent macular edema by co-performing grid photocoagulation.…”

Section: Discussionmentioning

confidence: 99%

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion

Ogino¹,

Tsujikawa²,

Murakami³

et al. 2011

OPTH

View full text Add to dashboard Cite

Purpose:To report the efficacy of grid photocoagulation combined with intravitreal bevacizumab (IVB) for macular edema recurring after previous IVBs associated with retinal vein occlusion (RVO).Methods:This retrospective study consisted of 19 eyes with branch retinal vein occlusion (BRVO) and nine eyes with central retinal vein occlusion (CRVO), which were treated with grid photocoagulation combined with IVB for recurrent macular edema after previous IVBs. The mean duration of total follow-up was 29.3 ± 5.8 months.Results:After this combination therapy, foveal thickness was reduced, significant with slight improvement in visual acuity (VA). At 1 month after treatment, although 25 of the 28 eyes showed complete resolution of the cystoid space, the macular edema recurred to some extent in 19 eyes. Compared with initial values, final foveal thickness was reduced significantly in both BRVO and CRVO groups (P < 0.001), but improvement in VA was significant only for eyes with BRVO (P = 0.012). The total number of IVB was 2.8 ± 0.7 for eyes with either BRVO or CRVO.Conclusion:Grid photocoagulation combined with IVB has a substantial effect on reducing recurrent macular edema associated with RVO, but the effect on visual acuity is limited.

show abstract

Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion

Cited by 4 publications

References 3 publications

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Comparison of Choroidal Thickness Changes following Intravitreal Dexamethasone, Ranibizumab, and Triamcinolone in Eyes with Retinal Vein Occlusion

Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion

Grid photocoagulation combined with intravitreal bevacizumab for recurrent macular edema associated with retinal vein occlusion

Contact Info

Product

Resources

About